Aclaris Therapeutics ACRS Institutional Ownership

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is held by 150 institutional investors per 13F filings through June 2026.

• Their combined ownership stood at 83.7% of outstanding shares in June 2026, down from 84.4% in March 2026.
• They increased total shares held in ACRS by 12.03% quarter over quarter, and investors in Aclaris Therapeutics increased 61.29% from a year ago.
• Of these 150 holders, 95 added to their stakes in Aclaris Therapeutics, 32 trimmed positions, and 23 made no changes.
• Altogether, these fund groups held 119.49Mn shares in ACRS by June 2026, up by 12.83Mn shares quarter on quarter, and up 32.87Mn shares year over year.
• RA CAPITAL MANAGEMENT, L.P. holds the largest position in ACRS at 12.72Mn shares as of June 30, 2026, or 8.91% of shares outstanding.
• The largest buyers of Aclaris Therapeutics for the quarter ending June 2026 were RA CAPITAL MANAGEMENT, L.P. (5.92Mn), BlackRock, Inc. (2.63Mn), SILVERARC CAPITAL MANAGEMENT, LLC (1.95Mn), Jones Hill Capital LP (1.76Mn), State Street Corp (1.25Mn).
• The biggest sellers of Aclaris Therapeutics for the quarter ending June 2026 included Morgan Stanley (2.61Mn), BML Capital Management, LLC (2.28Mn), BALYASNY ASSET MANAGEMENT L.P. (1.34Mn), CITADEL ADVISORS LLC (487.24K), D. E. Shaw & Co., Inc. (486.3K).
• According to Business Quant data, leading holders of ACRS for June 2026 are RA CAPITAL MANAGEMENT, L.P. (12.72Mn), BML Capital Management, LLC (11.98Mn), BlackRock, Inc. (10.04Mn), Deep Track Capital, LP (9.34Mn), Vivo Capital, LLC (6.69Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.82Mn), Frazier Life Sciences Management, L.P. (4.93Mn), Rock Springs Capital Management LP (4.33Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (4.07Mn), Decheng Capital LLC (4.04Mn).